Cargando…

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer

Purpose: To analyze the prognostic factors and optimal response interval for stereotactic body radiotherapy (SBRT) in patients with lung oligometastases (OM) or oligoprogression (OP) from colorectal cancer (CRC). Method: Patients with lung OM or OP from CRC treated by SBRT at our hospital were inclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuai, Dong, Dezuo, Geng, Jianhao, Zhu, Xianggao, Shi, Chen, Zhang, Yangzi, Wang, Hongzhi, Zhou, Shun, Wu, Hao, Cai, Yong, Li, Yongheng, Wang, Weihu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803520/ https://www.ncbi.nlm.nih.gov/pubmed/31681609 http://dx.doi.org/10.3389/fonc.2019.01080

Ejemplares similares

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors
por: Ji, Xiaoqin, et al.
Publicado: (2021)

One to Two Cycles of Consolidation Chemotherapy With Capecitabine After Neoadjuvant Chemoradiotherapy Does Not Benefit Low-Risk Patients With Locally Advanced Middle-Low Rectal Cancer
por: Sheng, Xueqing, et al.
Publicado: (2021)

Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion
por: Zhao, Yuting, et al.
Publicado: (2019)

Hyperfractionation versus Conventional Fractionation of Preoperative Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer: A Propensity Score Matching Study
por: Shi, Chen, et al.
Publicado: (2022)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
por: Ho, Chin-Beng, et al.
Publicado: (2023)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
por: Wang, Hongzhi, et al.
Publicado: (2022)

Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients With Clinically Positive Lateral Pelvic Lymph Node
por: Li, Shuai, et al.
Publicado: (2021)

Corrigendum: Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients with Clinically Positive Lateral Pelvic Lymph Node
por: Li, Shuai, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Dentate line invasion as a predictive factor of poor distant relapse-free survival in locally advanced lower rectal cancer with anal sphincter involvement
por: Song, Maxiaowei, et al.
Publicado: (2022)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Effect of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) and Non-Operative Strategy on Outcomes of Distal Rectal Cancer Patients with Clinically Positive Lateral Pelvic Lymph Node
por: Li, Shuai, et al.
Publicado: (2021)

Stereotactic radiotherapy for lung oligometastases
por: Falcinelli, Lorenzo, et al.
Publicado: (2022)

Stereotactic radiotherapy for liver oligometastases
por: Menichelli, Claudia, et al.
Publicado: (2022)

Stereotactic radiotherapy for adrenal oligometastases
por: Borghesi, Simona, et al.
Publicado: (2022)

Stereotactic radiotherapy for bone oligometastases
por: Colosimo, Caterina, et al.
Publicado: (2022)

Stereotactic radiotherapy for brain oligometastases
por: Lupattelli, Marco, et al.
Publicado: (2022)

Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma
por: Yamamoto, Takaya, et al.
Publicado: (2020)

Excluding the ischiorectal fossa irradiation during neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy followed by abdominoperineal resection decreases perineal complications in patients with lower rectal cancer
por: Song, Maxiaowei, et al.
Publicado: (2019)

Stereotactic radiotherapy for oligometastases in the lymph nodes
por: Pasqualetti, Francesco, et al.
Publicado: (2022)

Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases†
por: Yamashita, Hideomi, et al.
Publicado: (2016)

Stereotactic Body Radiotherapy for Lymph Node Oligometastases: Real-World Evidence From 90 Consecutive Patients
por: Burkon, Petr, et al.
Publicado: (2021)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years
por: Aujla, Khush S., et al.
Publicado: (2019)

MRI-based radiomics to predict neoadjuvant chemoradiotherapy outcomes in locally advanced rectal cancer: A multicenter study
por: Xiang, Yirong, et al.
Publicado: (2022)

Feasibility of split-course stereotactic ablative radiotherapy for oligometastases
por: Paik, Eun Kyung, et al.
Publicado: (2018)

Stereotactic Radiotherapy for Oligometastases in Lymph Nodes—A Review
por: Matsushita, Haruo, et al.
Publicado: (2018)

MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer
por: Song, Maxiaowei, et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases
por: Kalinauskaite, Goda G., et al.
Publicado: (2020)

Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases
por: Sutera, Philip, et al.
Publicado: (2018)

Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study
por: Du, Rongxu, et al.
Publicado: (2022)

Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Jingu, Keiichi, et al.
Publicado: (2018)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China
por: Xu, Chenyang, et al.
Publicado: (2022)

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience
por: Tahover, Esther, et al.
Publicado: (2018)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
por: Habl, Gregor, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ksgs16h9tjjpcashbd9ima9g3b